The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome

Endocrine Journal

Volumn 59, Issue 10, 2012, Pages 889-894

  Senda, Miho ^a   Ogawa, Susumu ^a,b   Nako, Kazuhiro ^a   Okamura, Masashi ^a,c   Sakamoto, Takuya ^a   Ito, Sadayoshi ^a  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Ghrelin; Glucagon like peptide 1; Hyperphagia; Prader Willi syndrome; Visceral adipose tissue

Indexed keywords

ADIPONECTIN; BIGUANIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LEPTIN; LIRAGLUTIDE; PIOGLITAZONE; SITAGLIPTIN;

ADULT; APPETITE; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERPHAGIA; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; MONOTHERAPY; OBESITY; PRADER WILLI SYNDROME; SATIETY; SUBCUTANEOUS FAT;

ABDOMINAL FAT; ADULT; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERPHAGIA; PRADER-WILLI SYNDROME;

EID: 84869223653     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ12-0074     Document Type: Article

References (25)

1. Prader A, Labhart A, Willi H (1956) A syndrome characterised by obesity, dwarfism (small stature, small hands and feet), hypogonadism, pre and postnatal muscular hypotonia and mental retardation. Schweiz Med Wochenschr 86: 1260-1261 (In German).
2. Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, et al. (1993) Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 91: 398-402.
3. Purtell L, Sze L, Loughnan G, Smith E, Herzog H, et al. (2011) In adults with Prader-Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels. Neuropeptides 45: 301-307.
4. Nauck MA (2011) Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 124: S3-18.
5. Bagger JI, Christensen M, Knop FK, Vilsboll T (2011) Therapy for obesity based on gastrointestinal hormones. Rev Diabet Stud 8: 339-347.
6. Seetho IW, Jones G, Thomson GA, Fernando DJ (2011) Treating diabetes mellitus in Prader-Willi syndrome with Exenatide. Diabetes Res Clin Pract 92:e1-2.
7. Cyganek K, Koblik T, Kozek E, Wojcik M, Starzyk J, et al. (2011) Liraglutide therapy in Prader-Willi syndrome. Diabet Med 28:755-756.
8. Lee S, Yabe D, Nohtomi K, Takada M, Morita R, et al. (2010) Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr J 57:119-126.
9. Yabe D, Watanabe K, Sugawara K, Kuwata H, Kitamoto Y, et al. (2012) Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes. J Diabet Invest 3: 70-79.
10. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity (2002) New criteria for 'obesity disease' in Japan. Circ J 66:987-992.
11. van der Kooy K, Seidell JC (1993) Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord 17:187-196.
12. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL (2012) Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344: d7771.
13. Monami M, Marchionni N, Mannucci E (2009) Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 160:909-917.
14. Haqq AM, Muehlbauer MJ, Newgard CB, Grambow S, Freemark M (2011) The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index. J Clin Endocrinol Metab 96: E225-232.
15. Scerif M, Goldstone AP, Korbonits M (2011) Ghrelin in obesity and endocrine diseases. Mol Cell Endocrinol 340: 15-25.
16. Goldstone AP, Thomas EL, Brynes AE, Castroman G, Edwards R, et al. (2004) Elevated fasting plasma ghrelin in prader-willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance. J Clin Endocrinol Metab 89:1718-1726.
17. DelParigi A, Tschöp M, Heiman ML, Salbe AD, Vozarova B, et al. (2002) High circulating ghrelin: a potential cause for hyperphagia and obesity in prader-willi syndrome. J Clin Endocrinol Metab 87:5461-5464
18. Tauber M, Conte Auriol F, Moulin P, Molinas C, Delagnes V, et al. (2004) Hyperghrelinemia is a common feature of Prader-Willi syndrome and pituitary stalk interruption: a pathophysiological hypothesis. Horm Res 62:49-54.
19. Saad MF, Bernaba B, Hwu CM, Jinagouda S, Fahmi S, et al. (2002) Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab 87:3997-4000.
20. Dezaki K, Hosoda H, Kakei M, Hashiguchi S, Watanabe M, et al. (2004) Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents. Diabetes 53: 3142-3151.
21. Imeryüz N, Yeǧen BC, Bozkurt A, Coşkun T, Villanueva-Peñacarrillo ML, et al. (1997) Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273: G920-927.
22. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, et al. (2005) The inhibitory effects of peripheral administration of peptide YY (3-36) and GLP-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044:127-131.
23. Page AJ, Slattery JA, Milte C, Laker R, O'Donnell T, et al. (2007) Ghrelin selectively reduces mechanosensitivity of upper gastrointestinal vagal afferents. Am J Physiol Gastrointest Liver Physiol 292:G1376-1384.
24. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, et al. (2002) The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123:1120-1128.
25. Sze L, Purtell L, Jenkins A, Loughnan G, Smith E, et al. (2011) Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 96: E1314-1319.